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Ceramid¢ has been suggested as an intracetlular modulator of cell 8rowtll and differentiation [Okazaki. T. ¢t al. (1990) J. Biol. Chem. 265, 
15823-!5831]. In this study, parameters that modulate the effects of ceramide on HL-60 cell growth and differentiation were examined. A
short-chain, ¢~ll-pcrmeabl¢ analog of ¢eramide, C,-ceramide. induced ifferentiation f HL-60 human leukemia cells and inhibited HL.60 growth 
in a concentration-dependent manner. The potency of C:-¢¢ramide was modulated by the starting cell density such that the concentration f
C,-ceramide producing 50% inhibition of cell growth (ICon,) ranged from 2,uM (for cells suspended at 1 × 10 ~ c¢lls/ml) to I 1/~M (for cells at 
× 10 ~ celts/ml). Ho~vever, the IC~ showed little variation if the concentration f C~-ceramide ~'as expressed as fmol of C:-ceramide per t0 s ceils. 
Therefore, the effectiveness of C,-¢eramid¢ appeared to be primarily determined by its celhdar ather than molar concentration. Binding of 
C,-ceramid¢ to serum proteins resulted in a 10.1"old increase in the IC50~. These results demonstrate that the biologic activity of C,:ceramide is subj~t 
to surface dilution kinetics and is sensitive to the presence of lipid-binding proteins. In these properties, ceramide behaves as a prolotypi¢ lipid 
second me~senger/intracellular mediator. 
Ceralrtide; Cell growth: Cell differentiation: Signal transduction; Sphingotlpid 
1. INTRODUCTION 
Recent studies have led to the identification of a 
sphingomyelin cycle, whereby the action ofextragellular 
agents uch as 1,25-dihydroxyvitamin D.~ [1], tumor ne- 
crosis factor-or and y-interferon [2] results in activation 
of a neutral sphingomyelinase. This causes the hydroly- 
sis of membrane sphingomyelin and the generation of 
intracellular ceramide. Studies with bacterial sphin- 
gomyelinase and with cell-permeable analogs of cer- 
amide suggest an important role for ceramide in the 
regulation of cell proliferation and differentiation [1-3]. 
Thus, short-chain ceramides were shown to inhibit HL- 
60 cell proliferation and to induce monocytic differenti- 
ation of' these leukemia cells [2,3]. Although these short- 
chain ceramide analogs, such as C2-ceramide (N-aee- 
tylsphingosine), have significantly more water solubility 
than natural ceramides, they nevertheless exhibit special 
properties as pharmacologic agents. They are am- 
phiphilic molecules that are presumably active in the 
context of cell membranes ( ince they mimic the action 
of ceramide, art endogenous membrane lipid). 
In our studies with C2-eeramide, we found significant 
inter-experiment variability in the potency ofceramide; 
however, within an individual experiment, eeramide 
demonstrated very consistent effects (for example see 
Fig. 1), This variability was reminiscent of studies with 
sphingosine, another biologically active amphiphilic 
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sphingolipid. In the case of sphingosine, biologic activ- 
ity was modulated by the ratio of sphingosine to cell 
number [4] and by the presence or absence of lipid- 
binding proteins (such as bovine serum albumin or fetal 
call' serum [4,5]). Therefore, we examined the effects of 
these parameters on the action of C.,-ceramide. 
2. EXPERIMENTAL 
2.1. C:.ceramide 
C2.ceramide was synthesized as previously described [3]. 
2.2. HL.60 celt proh~fi, ration attd d(lferet;tiation 
HL-60 human myelocytic leukemia cells were purchased from 
ATCC and used between passages 20 and 45. The cells were grown 
in RPMI 1640 medium containing 10% fetal calf ~rum at 37°C in a 
5% CO, incubator at densities ranging between I x 10-' cells/ml to 1 
x l0 s cells/ml. The cells were washed once with phosphate-buffered 
saline and resuspended in serum-free media containing insulin (5 me/l) 
and transferrin (5 me/l) for 2-3 h. Cells were then treated with Ca- 
ceramide or with ethanol vehicle (ethanol concentration was less than 
0.1%). For all reported experiments, cell viability was greater than 
80%. For some experinaents (Fig. 3), C.,-ceramide was delivered in a 
I: 1 complex with bovine serum albumin, as indicated in the telex'ant 
figure legend. Cells were counted using a hemocytometer, and cell 
viability was evaluated by Trypan blue dye exclu6ion. HL-60 cell 
differentiation was analy~d by measuring H:O_, production i  a micro 
assay as described 16,7]. 
3. RESULTS 
In serum-free media, C.,..ceramide was a potent inhib- 
itor of HL-60 cell proliferation (Fig. IA). In the exper- 
iment shown in Fig. IA, C,-ceramide at 2.5/JM pro- 
duced near total inhibition of HL-60 cell proliferation 
Published by Elsevier Science Publishers It. V. 21 1 
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Fig. 1. Effects of C,-¢eramide on HL-60 growd~ and dilTerentiatJon. (A) Time and concentration dependence of HL-60 growth on C~-eeramide, 
HL-6O cells in serum-free media were treated with the indicated concentrations of C:-ceramide and cell number wa~ determined at the indicated 
time point~, These results are representative of more than 10 experiments. (B)Effects of C,.ceramide onH,O~ generation. HL.60 ceils were treated 
with or without |.25-dihydro~yvitamin D.~ (0.3 nM) in the pl~senee of the indicated concentrations f C~,-¢ernm/de. Differemiation was monitored 
by the ability of differentiated HL.60 cells to generate H,O.~ following 3 d0ys of treatment with C.,-¢¢ramide, These results are averages of2 
determinations a d are represetatative of 6 eaperiments. 
without significant cell death. Higher concentrations re- 
suited in increasing cytotoxic effects (data not shown). 
The precise concentration of C2-ceramide required to 
produce growth stasis (e,g. 2.5 t im in Fig. 1) varied 
from experiment to experiment but was always less than 
cytotoxic oncentrations (e.g. >5-10/zM). 
C2-ceramide alone or in combination with low con- 
centrations of 1,25-dihydroxyvitamin D~ resulted in sig- 
nificant induction of HL-60 cell differentiation as 
judged by the ability to induce NBT-reducing activity 
[1,3] and the ability to induce H.,O, production (Fig. 
1B). The dose response for induction of H.~O2 resembled 
that required for inhibition of cell growth with maximal 
stimulation of differentiation (H,.O2 production) occur- 
ring in response to 2.5 aM of C.,-¢eramide. The ability 
of C2-ceramide to induce differentiation suggests that 
ceramide is activating a pathway that is involved i n  
regulation of cell proliferation and differentiation and 
that the effects on cell proliferation are unlikely to be 
due to non-specific action of ceramide. 
We next addressed the question of whether starting 
cell density was an important parameter in modulating 
ceramide potency. HL-60 cells at different starting cell 
densities were treated with variable concentrations of
C~-ceramide, and proliferation was monitored (Fig. 2). 
C~-ceramide was able to inhibit HL-60 cell growth in a 
dose-dependent manner at all starting cell densities 
(Fig. 2A). However, it became obvious that the potency 
of ceramide was modulated significantly by the starting 
cell density. For example, C2-ceramide was much more 
potent in inhibiting HL-60 cell growth at the lower 
starting cell density of 1 × 10 s cells/ml than at higher cell 
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Fig. 2. Modulation of efficacy of C:-ceramide by starting cell density. (A) HL-60 cells were suspended at different cell densities as indicated. At 
each starting cell density. H L-60 cells were treated with increasing concentrations of C,-eeramide, and cell growth was monitored at 3 days. These 
results are representative of 3 experiments. (B) The concentration ofC,-ceramide producing 50% inhibition was plotted as a function of starting 
density of HL-60 cells. These results are representative of 3 experiments. 
densities. In order to quantitate these effects, the con- 
centration of ceramide required to produce 50% inhibi- 
tion of cell growth was plotted as a function of starting 
cell density (Fig. 2B). These results how that ceramide 
potency is inversely proportional to starting cell density. 
Since the slope of the line is close to 1, a useful opera- 
tional rule suggests that doubling cell density would 
require doubling ceramide concentrations to achieve the 
same effect. This rule, however, is limited by the solubil- 
ity ofceramide inserum.free media. We have found that 
in the absence of serum proteins, the solubility of C:- 
ceramide isapproximately 10-15/JM (data not shown). 
Therefore, the experimental conditions to evaluate bio- 
logic activities of C2-ceramide should be restricted to 
concentrations of C.,-ceramide below 10-15 /zM. In 
turn, this defines the upper limit of starting cell densi. 
ties, since progressively increasing cell density cannot be 
matched by increasing C.,-ceramide above 10-15 ,uM. 
The progressive loss of ceramide potency with in- 
creasing starting cell density suggests that the potency 
of ceramide is determined primarily by the cell concert. 
tratlon of ceramide rather than the bulk molar concen- 
tration. This is expected for a molecule that presumably 
acts in membranes rather than in the fluid phase, as was 
shown with sphingosine ffects on protein kinase C 
[4,8,9]. Therefore, when the concentrations of ceramide 
were recalculated as moles of C:-ceramide per cell, the 
potency of ceramide appeared to be hardly modulated 
Since this parameter most probably reflects he partitioning of ¢¢ra- 
mide into melnbmnes, the effective concentration of C.,-¢eramide 
(expressed asreel/cells) may also vary between different cell types 
depending oncell size, th0 total membrane surface per cell, and total 
lipid content of the cells [10]. 
by starting cell density (data not shown). The ICse, was 
approximately 10-20 fmol/cell at all cell densities evalu- 
ated. Therefore, in designing experiments aimed at dis- 
cerning biologic activities of C2-ceramide, the initial 
concentration range should be defined by the ratio of 
C2-ceramide to starting cell density rather than by the 
bulk molar concentrationJ 
The potency of C.~-ceramide was dramatically modu. 
luted by the presence of fetal calf serum during treat- 
ment of HL-60 cells (Fig. 3). Thus, C2-ceramide became 
much less potent and the useful concentration range at 
a given cell density was shifted approximately one log 
higher so that the ICs0~ became approximately 30/.tM. 
This is presumably due to the presence of serum pro- 
teins (especially albumin) that may act to bind C2-cer- 
amideo thus reducing its effective concentration a d in- 
creasing its solubility. This was borne out when C2- 
eeramide was delivered in a 1:1 complex with fatty acid- 
free bovine serum albumin to cells grown in the absence 
of fetal calf serum. Under these conditions, the dose. 
dependence on C:-ceramide was also shifted signifi- 
cantly to the right and resembled that seen in the pres- 
ence of fetal calf serum (Fig. 3). 
4. DISCUSSION 
The results from this study offer a better understand- 
ing of parameters that determine biologic activities of 
eeramide. 
C:..ceramide is an amphipathic ' ell-permeable' ana- 
log of ceramide which has become instrumental in de- 
fining biologic activities of ceramide [2,3]. The delin~- 
tion of parameters that determine its pharmacologic/ 
biologic applica'fion should therelbre nhance the abil- 
ity to determine further biologic activities of ceramide. 
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Fig. 3, Modulation of clTects of C:-ceramide b~ proteins, HL-60 cells 
were treated with the indicated concentrations of C~-ceramide deliv. 
ered to cells grown in sgrum-fi'ee media (SFM), or to cells Brown in 
10% fetal calf serum (10% FCS), C:-ceramide wa~ also delivered as a 
1:1 complex with bovine serum albumin (C.-,/BSA) to cells grown in 
serum-free media, Cell counts were determined at 3 days followin8 
treatment, 
Moreover, these parameters should facilitate the exam- 
ination of potential intracellular molecular targets for 
the action of ceramide. 
The current studies have identified cell density and 
the presence of ceramide-binding proteins as very im- 
portant determinants of the potency of ceramide. Thus, 
the effective concentration f ceramide isdetermined by 
the ratio of total (free) ceramide to total cell number, 
and the tree effective concentration fceramide is mark- 
~' A standard component of most cell culture growth rnedia, 
edly influenced by the presence of ceramide-binding 
proteins such as bovine serum albumin or fetal calf 
serum.: These same considerations appear to apply in 
the determination f the action of sphingosine whereby 
the effectiveness of sphingosine is modulated by cell 
number and by the presence of serum proteins [4,5]. 
At this point, we may begin to generalize these con- 
siderations to the use of many amphiphilic ompounds 
which include a number of pharmacologic reagents and 
an increasing number of endogenous cell regulatory 
molecules such as diacylglycerols and fatty acids. Atten- 
tion to these factors is critical for the appropriate use 
of lipid mediators as regulators of cell function. 
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